*May 2020*
The first lung cancer patient to be treated with a new type of immunotherapy involving the re-engineering of a patient’s T cells, known as TCR T-cell therapy, took place at Winship Cancer Institute of Emory University (Winship) on May 7, 2020. The Winship patient is enrolled on a clinical trial evaluating the safety and tolerability of a TCR T-cell therapy product in patients with lung cancer. Read more.
